8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
May 1, 2026·SEC
Atara Biotherapeutics, Inc.(ATRA)Earnings, Financials & Key Ratios
ATRA•NASDAQ
$10.26
4.0× P/E·Price updated Jul 7, 2026
AboutAtara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Show more
- Revenue$121M-6.3%
- EBITDA$38M+148.4%
- Net Income$33M+138.3%
- EPS (Diluted)2.57+122.5%
- Gross Margin82.44%-1.5%
- EBITDA Margin31.45%+151.7%
- Operating Margin29.69%+145.9%
- Net Margin27.07%+140.9%
ATRA Price & Volume
Atara Biotherapeutics, Inc. (ATRA) stock price & volume — 10-year historical chart
Loading chart...
Revenue Collapse Exposes Critical Liquidity Solvency Risks
Investment Thesis • Updated 2026Q1
VerdictNegative: The company's cash and equivalents have dwindled to $8.4 million
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and solvency
Key Thesis Takeaways
- Atara Biotherapeutics faces a precarious outlook as its reliance on non-recurring milestone payments has resulted in a severe revenue contraction from $98.1 million in 2025Q1 to $516.0K in 2026Q1.
- The company's inability to establish a sustainable commercial model, combined with a persistent negative equity position of -$37.3 million, suggests significant long-term solvency concerns.
- Investors should monitor the company's limited cash runway of $8.4 million, which appears insufficient to support ongoing operations without further dilutive financing.
Verdict Logic
creating an imminent liquidity risk that necessitates immediate and likely dilutive capital intervention.
ATRA Growth Metrics
Atara Biotherapeutics, Inc. (ATRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years23.85%
TTM-88.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM39.47%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM81.99%
Return on Capital
10 Years0.29%
5 Years84.85%
3 Years251.45%
Last Year674.99%
ATRA Recent Earnings
Atara Biotherapeutics, Inc. (ATRA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.29+12.0%
$0.33
Rev
$516,000-82.2%
$3M
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.25-177.8%
$0.09
Rev
$2M-51.2%
$3M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.32+61.4%
$0.83
Rev
$3M+393.3%
$700,000
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.19+159.4%
$0.32
Rev
$18M+876.4%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.29vs $0.33+12.0% | $516,000vs $3M-82.2% |
| Q2 2026 | Mar 16, 2026 | $0.25vs $0.09-177.8% | $2Mvs $3M-51.2% |
| Q4 2025 | Nov 12, 2025 | $0.32vs $0.83+61.4% | $3Mvs $700,000+393.3% |
| Q3 2025 | Aug 11, 2025 | $0.19vs $0.32+159.4% | $18Mvs $2M+876.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Atara Biotherapeutics, Inc. (ATRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.26 | $92.44M | 3.99 | -6.33% | 27.07% | — | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $1.35 | $171.71M | -1.21 | 14.85% | -173.02% | — | — | |
| $3.10 | $505.47M | -1.89 | — | — | -131.58% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — |
Compare ATRA vs Peers
Atara Biotherapeutics, Inc. (ATRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATRA SEC Filings & Documents
Atara Biotherapeutics, Inc. (ATRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ATRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ATRA Frequently Asked Questions
Atara Biotherapeutics, Inc. (ATRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Atara Biotherapeutics, Inc.'s revenue?
Atara Biotherapeutics, Inc. (ATRA) reported $23.1M in revenue for fiscal year 2025.
How fast is Atara Biotherapeutics, Inc. growing?
Atara Biotherapeutics, Inc. (ATRA) saw revenue decline by 6.3% over the past year.
Is ATRA profitable?
Atara Biotherapeutics, Inc. (ATRA) reported a net loss of $9.5M for fiscal year 2025.
Dividend & Returns
What is Atara Biotherapeutics, Inc.'s free cash flow?
Atara Biotherapeutics, Inc. (ATRA) had negative free cash flow of $25.9M in fiscal year 2025, likely due to heavy capital investments.